Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MOREWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MOREUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.
EXPLORE MOREThis gene encodes a melanocyte-specific type I transmembrane glycoprotein. The encoded protein is enriched in melanosomes, which are the melanin-producing organelles in melanocytes, and plays an essential role in the structural organization of premelanosomes. This protein is involved in generating internal matrix fibers that define the transition from Stage I to Stage II melanosomes. This protein undergoes a complex pattern of prosttranslational processing and modification that is essential to the proper functioning of the protein. A secreted form of this protein that is released by proteolytic ectodomain shedding may be used as a melanoma-specific serum marker. Alternate splicing results in multiple transcript variants.
Loading...| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | Inquiry & Datasheet |
| CAR-T-1-M552-2 | Anti-gp100 VHH h(CD28) CAR, [T] | Human | GPA7 | Camelid | VHH-CD28 | Lentiviral | T cell | |
| CAR-T-3-M552-2BZ | Anti-gp100 VHH h(CD28-41BB-CD3ζ) CAR, [T] | Human | GPA7 | Camelid | VHH-CD28-41BB-CD3ζ | Lentiviral | T cell | |
| CAR-T-2-M552-2Z | Anti-gp100 VHH h(CD28-CD3ζ) CAR, [T] | Human | GPA7 | Camelid | VHH-CD28-CD3ζ | Lentiviral | T cell | |
| CAR-T-2-M552-2G | Anti-gp100 VHH h(CD28-FcεRIγ) CAR, [T] | Human | GPA7 | Camelid | VHH-CD28-FcεRIγ | Lentiviral | T cell | |
| CAR-T-3-M552-2XZ | Anti-gp100 VHH h(CD28-OX40-CD3ζ) CAR, [T] | Human | GPA7 | Camelid | VHH-CD28-OX40-CD3ζ | Lentiviral | T cell | |
| CAR-T-1-M552-Z | Anti-gp100 VHH h(CD3ζ) CAR, [T] | Human | GPA7 | Camelid | VHH-CD3ζ | Lentiviral | T cell | |
| CAR-T-2-M552-4Z | Anti-gp100 VHH h(CD4-CD3ζ) CAR, [T] | Human | GPA7 | Camelid | VHH-CD4-CD3ζ | Lentiviral | T cell | |
| CAR-T-2-M552-4G | Anti-gp100 VHH h(CD4-FcεRIγ) CAR, [T] | Human | GPA7 | Camelid | VHH-CD4-FcεRIγ | Lentiviral | T cell | |
| CAR-T-2-M552-8Z | Anti-gp100 VHH h(CD8-CD3ζ) CAR, [T] | Human | GPA7 | Camelid | VHH-CD8-CD3ζ | Lentiviral | T cell | |
| CAR-T-1-M552-G | Anti-gp100 VHH h(FcεRIγ) CAR, [T] | Human | GPA7 | Camelid | VHH-FcεRIγ | Lentiviral | T cell | |
| CAR-T-2-M552-BZ | Anti-gp100 VHH h(41BB-CD3ζ) CAR, [T] | Human | GPA7 | Camelid | VHH-41BB-CD3ζ | Lentiviral | T cell | |
| CAR-T-2-M552-CZ | Anti-gp100 VHH h(b2c-CD3ζ) CAR, [T] | Human | GPA7 | Camelid | VHH-b2c-CD3ζ | Lentiviral | T cell |
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.
LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MORE
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE
